Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT
- PMID: 31014683
- PMCID: PMC6482846
- DOI: 10.1016/j.oret.2018.11.011
Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT
Abstract
Purpose: Macular atrophy and scar increase in prevalence during treatment for neovascular age-related macular degeneration and are associated with poor visual acuity. We sought to identify the distribution of spectral-domain OCT (SD-OCT)-determined features and subretinal lesion thicknesses at sites of macular scar or atrophy after 2 years of treatment in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
Design: Cross-sectional analysis.
Participants: CATT participants with SD-OCT, color photographic (CP) and fluorescein angiogram (FA; CP/FA) images at year 2.
Methods: Sixty-eight study eyes at year 2 in CATT were selected based on image quality and CP/FA-determined predominant presence of the following: geographic atrophy (GA, n = 25), non-GA (NGA, n = 44), fibrotic scar (FS, n = 26), or non-FS (NFS, n = 7). The CP/FA components were delineated by CP/FA readers; SD-OCT morphologic features and thicknesses were delineated by OCT readers. Using custom software and graphic user interfaces, images were registered, overlaying features and components per pixel; differences were analyzed across groups.
Main outcome measures: OCT features, CP/FA components, and retinal and subretinal lesion thicknesses at each pixel of regional overlays.
Results: SD-OCT assessment of registered areas of pathology revealed the following: (1) retinal pigment epithelium atrophy (with or without residual lesion material) covered 75% of pixels designated as GA, 22% of NGA, 24% of NFS, and 46% of FS (P < 0.001). (2) Photoreceptor layer thinning covered 85% of GA, 42% of NGA, 33% of NFS, and 59% of FS (P < 0.001). (3) Subretinal lesion features covered 31% of GA, 42% of NGA, 85% of NFS, and 92% of FS (P < 0.001). Mean thickness of the subretinal lesion complex (measured in microns ± standard deviation) differed among GA (48±25 μm), NGA (61±35 μm), NFS (83±17 μm), and FS (151±74 μm) (P < 0.001). In eyes with GA, the thickness was greater in areas with residual lesion (51.4±27 μm) than in those without (27.2±9 μm).
Conclusions: Retinal pigment epithelium atrophy and photoreceptor layer thinning are common not only in areas of macular atrophy but also in areas of FS. Photoreceptor loss extends beyond the areas of clinically apparent atrophy and FS. Subretinal lesion components were common in areas of scar, but they were also present in nearly one-third or more of areas of macular atrophy.
Trial registration: ClinicalTrials.gov NCT00593450.
Copyright © 2018 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Figures



Similar articles
-
Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials.Am J Ophthalmol. 2021 Mar;223:338-347. doi: 10.1016/j.ajo.2020.11.002. Epub 2020 Nov 19. Am J Ophthalmol. 2021. PMID: 33221285 Free PMC article. Clinical Trial.
-
Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials.Ophthalmology. 2019 May;126(5):743-751. doi: 10.1016/j.ophtha.2018.11.020. Epub 2018 Nov 23. Ophthalmology. 2019. PMID: 30476517 Free PMC article. Clinical Trial.
-
Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.Ophthalmology. 2016 Apr;123(4):865-75. doi: 10.1016/j.ophtha.2015.12.002. Epub 2016 Jan 9. Ophthalmology. 2016. PMID: 26783095 Free PMC article. Clinical Trial.
-
Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration.Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT14-26. doi: 10.1167/iovs.16-19969. Invest Ophthalmol Vis Sci. 2016. PMID: 27409464 Free PMC article. Review.
-
Structural OCT and OCT angiography biomarkers associated with the development and progression of geographic atrophy in AMD.Graefes Arch Clin Exp Ophthalmol. 2024 Nov;262(11):3421-3436. doi: 10.1007/s00417-024-06497-8. Epub 2024 Apr 30. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 38689123 Free PMC article. Review.
Cited by
-
Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial.JAMA Ophthalmol. 2020 May 1;138(5):510-518. doi: 10.1001/jamaophthalmol.2020.0437. JAMA Ophthalmol. 2020. PMID: 32191267 Free PMC article. Clinical Trial.
-
Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials.Am J Ophthalmol. 2021 Mar;223:338-347. doi: 10.1016/j.ajo.2020.11.002. Epub 2020 Nov 19. Am J Ophthalmol. 2021. PMID: 33221285 Free PMC article. Clinical Trial.
-
Non-exudative OCT findings in neovascular AMD.Eye (Lond). 2025 Feb;39(3):516-526. doi: 10.1038/s41433-024-03461-y. Epub 2024 Nov 25. Eye (Lond). 2025. PMID: 39587331 Review.
-
Photoreceptor Degeneration: More Than a Bystander in Age-Related Macular Degeneration.Adv Exp Med Biol. 2025;1468:27-31. doi: 10.1007/978-3-031-76550-6_5. Adv Exp Med Biol. 2025. PMID: 39930168 Review.
-
Cytochrome P450 oxidase 2J inhibition suppresses choroidal neovascularization in mice.Metabolism. 2022 Sep;134:155266. doi: 10.1016/j.metabol.2022.155266. Epub 2022 Jul 19. Metabolism. 2022. PMID: 35868524 Free PMC article.
References
-
- Sadda SR, Tuomi LL, Ding B, et al. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology 2018. - PubMed
-
- Abdelfattah NS, Al-Sheikh M, Pitetta S, et al. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. Ophthalmology 2017;124(2):215–23. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous